Orphan-Drug Designation request of NK Cell Product oNKordĀ® granted by FDA

April 20, 2016 On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKordĀ® for treatment of acute myeloid leukemia (AML)